1,433
Views
115
CrossRef citations to date
0
Altmetric
Review

Diagnosis and management of xerostomia and hyposalivation

, &
Pages 45-51 | Published online: 22 Dec 2014

Abstract

Xerostomia, the subjective complaint of dry mouth, and hyposalivation remain a significant burden for many individuals. Diagnosis of xerostomia and salivary gland hypofunction is dependent upon a careful and detailed history and thorough oral examination. There exist many options for treatment and symptom management: salivary stimulants, topical agents, saliva substitutes, and systemic sialogogues. The aim of this review is to investigate the current state of knowledge on management and treatment of patients affected by xerostomia and/or hyposalivation.

Introduction

Xerostomia is defined as the subjective complaint of dry mouth.Citation1 Interestingly, patients complaining of xerostomia frequently do not show any objective sign of hyposalivation and their symptoms may be secondary to qualitative and/or quantitative changes in the composition of saliva.Citation2,Citation3 The normal stimulated salivary flow rate averages 1.5–2.0 mL/min while the unstimulated salivary flow rate is approximately 0.3–0.4 mL/min.Citation4,Citation5 A diagnosis of hyposalivation is made when the stimulated salivary flow rate is ≤0.5–0.7 mL/min and the unstimulated salivary flow rate is ≤0.1 mL/min.Citation5Citation7 Xerostomia in patients with objective hyposalivation is diagnosed when the rate of saliva flow is less than the rate of fluid absorption across the oral mucosa plus the rate of fluid evaporation from the mouth.Citation8

Chronic xerostomia remains a significant burden for many individuals. In particular, it may affect speech, chewing, swallowing, denture-wearing, and general well-being.Citation9 Xerostomia secondary to hyposalivation may also result in rampant dental caries, oral fungal infections (eg, candidiasis), taste changes, halitosis, or burning mouth.Citation5,Citation10,Citation11 The most frequent cause of hyposalivation is the use of certain medications (such as anticoagulants, antidepressants, antihypertensives, antiretrovirals, hypoglycemics, levothyroxine, multivitamins and supplements, non-steroidal anti-inflammatory drugs, and steroid inhalers) (Villa et al, unpublished data, 2014), followed by radiotherapy to the head and neck, and Sjögren’s syndrome.Citation12 Other factors include depression, anxiety and stress, or malnutrition.Citation13

The prevalence of xerostomia in the population ranges from 5.5% to 46%. Studies have shown differences in the prevalence between the sexes and xerostomia appears to increase with increasing age. A possible explanation is that older individuals take several xerogenic drugs for their chronic conditions and this may lead to an overall reduction of the unstimulated salivary flow rate.Citation1,Citation10,Citation12,Citation14Citation18 Xerostomia remains an unresolved common complaint especially among the geriatric population, despite seeking medical or dental consultation.Citation19 The aim of this review is to explore the current state of knowledge on management and treatment of patients affected by xerostomia and hyposalivation.

Diagnosis of xerostomia and salivary gland hypofunction

The diagnosis of xerostomia and salivary gland hypofunction requires a thorough medical history. Particular attention should be given to the reported symptoms, medication use, and past medical history.

Patients with salivary gland hypofunction typically complain of dry mouth, difficulty swallowing and/or speaking; they hardly tolerate spicy, acidic, and crunchy food and often times report taste changes or difficulty wearing dentures.Citation20

Several questionnaires have been proposed to identify patients with xerostomia and hyposalivation. Fox et al developed a questionnaire on the severity of dry mouth, which may predict true hyposalivation ().Citation21 A positive answer to all the questions was associated with low saliva flow rates. A few years later, Thomson et al created an eleven-item summated rating scale on the severity of chronic xerostomia (Xerostomia Inventory).Citation22 Each response was scored and summed to give a final score. van der Putten et al shortened the Xerostomia Inventory and proposed the Summated Xerostomia Inventory-Dutch. Only five items were included.Citation2 In the questionnaire developed by Sreebny and Valdini, the question “does your mouth usually feel dry” was found to have had a sensitivity of 93%, a specificity of 68%, a negative predictive value of 98%, and a positive predictive value of 54% for hyposalivation.Citation23 Eisbruch et al studied the grade of xerostomia through a validated scale made of three grades ().Citation24 Finally, Pai et al proposed an eight-item visual analogue scale with which patients were asked to score their xerostomia.Citation25

Table 1 Questionnaires to assess dry mouth

One of the major risk factors for xerostomia and hyposalivation is the use of certain medications. In addition, polypharmacy has been shown to significantly influence patients’ saliva flow.Citation10,Citation26 “Xerogenic” medications associated with a low unstimulated saliva flow are: psycholeptics, psychoanaleptics (particularly selective serotonin reuptake inhibitors), oral antidiabetics (mainly sulfonylureas), respiratory agents, quinine, antihypertensive agents (such as thiazides and calcium channel blockers), urinary antispasmodics, glucosamine, non-steroidal anti-inflammatory drugs, opioids, ophthalmologicals, and magnesium hydroxide.Citation7,Citation27 Clinicians should review the drug history carefully in order to identify medications that can reduce the saliva flow in patients complaining of xerostomia. Finally, a thorough medical history should be obtained in order to identify other known causes of xerostomia such as Sjögren’s syndrome, radiation treatment of the head and neck region, and other systemic diseases (particularly hypertension, asthma, diabetes mellitus, hematological diseases, thyroid diseases, rheumatic diseases, psychiatric diseases, and eating disorders).

A careful oral examination is fundamental to identify clinical signs pathognomonic for hyposalivation. Several helpful signs have been proposed by Osailan et al: 1) sticking of an intraoral mirror to the buccal mucosa or tongue; 2) frothy saliva; 3) no saliva pooling in floor of mouth; 4) loss of papillae of the tongue dorsum; 5) altered/smooth gingival architecture; 6) glassy appearance to the oral mucosa (especially the palate); 7) lobulated/deeply fissured tongue; 8) cervical caries (more than two teeth); and/or 9) mucosal debris on palate (except under dentures).Citation28

Measurement of salivary flow rates

Most of the methods to measure the salivary flow are easy to perform and require little time. Salivary flow rates are usually measured for at least 5 minutes after an overnight fast or 2 hours after a meal.Citation29 Unstimulated whole salivary flow rate is assessed with the patient seated in an upright position. Patients are asked to constantly drain saliva from the lower lip into a graduated container for 15 minutes (draining method).Citation30 Leal et al proposed to collect saliva with preweighed cotton rolls placed at the orifices of the ducts of the major salivary glands and then reweigh them after the collection time.Citation14 The saliva can also be collected using a graduated absorbent strip placed on the floor of the mouth (readings at 1, 2, and 3 minutes).Citation31 Other methods to assess the unstimulated whole salivary flow rate include the spitting method and the suction method.Citation14,Citation30 Stimulated salivary flow rate is measured after the patient has chewed an unflavored gum base or paraffin wax (1–2 g) for 1 minute.Citation32 Otherwise, saliva production can be stimulated with a solution of 2% citric acid placed on the sides of the tongue at intervals of 30 seconds. The saliva is then collected into a graduated cylinder for 5 minutes. Salivary flow (both stimulated and unstimulated) can also be measured selectively from one major salivary gland or minor salivary gland. The parotid gland secretion is typically collected by using a suction device and placing a cup (the Lashley or Carlson–Crittenden cup) over the Stensen duct.Citation33 The submandibular gland salivary flow rate can be measured by incannulation of the Wharton’s duct.Citation34 A similar system to measure the salivary flow rates for both the sublingual and submandibular glands has been developed by Wolff et al.Citation35 Minor salivary gland salivary flow can be measured with micropipette and absorbent filter paper (the Periotron® method; ProFlow™ Inc, Amityville, NY, USA).Citation36 Flow rates can be calculated in units of μL/min/cm2 of mucosal area.Citation37

Management and treatment of xerostomia

Several treatment strategies for the management of xerostomia have been proposed in the past years and they all aim to reduce patients’ symptoms and/or increase salivary flow. Easy remedies are proper hydration; increase in humidity at night-time; avoidance of irritating dentifrices and crunchy/hard foods; and use of sugar-free chewing gums/candy.Citation38 Medications include mucosal lubricants, saliva substitutes, and saliva stimulants.

Systemic sialogogues

Pilocarpine and cevimeline are two systemic US Food and Drug Administration-approved sialogogues for treatment of dry mouth. Their effect depends on the presence of functional glandular tissue. Oral pilocarpine is a parasympathomimetic medication with muscarinic action.Citation39,Citation40 Cevimeline is a salivary gland stimulant with a stronger affinity for M3 muscarinic receptors.Citation41Citation44 Pilocarpine and cevimeline provide a similar benefit in patients with dry mouth.Citation45 Pilocarpine is typically administered at a dose of 5 mg three times a day for at least 3 months and cevimeline is prescribed at a dose of 30 mg three times a day for at least 3 months.Citation46 Side effects include: excessive sweating, cutaneous vasodilatation, emesis, nausea, diarrhea, persistent hiccup, bronchoconstriction, hypotension, bradycardia, increased urinary frequency, and vision problems. Both pilocarpine and cevimeline are relatively contraindicated in patients with uncontrolled asthma or chronic pulmonary disease and in β-adrenergic blocker users, and should be used with caution in patients with active gastric ulcers or uncontrolled hypertension. Pilocarpine is also contraindicated in individuals with narrow-angle glaucoma and iritis, and should be used with caution in individuals with chronic pulmonary disease, asthma, or cardiovascular diseases.Citation40

Other sialogogues

Anethole trithione is a cholagogue that has been shown to improve oral symptoms and increase the salivary flow in patients with xerostomia and hyposalivation.Citation47 More studies are necessary to prove the efficacy of this medication. Patients who were treated with psychotropic drugs (tricyclic antidepressants or neuroleptics) and were suffering from xerostomia benefited from yohimbine use, an alpha 2 adrenoceptor antagonist.Citation48

Intraoral topical agents

Intraoral topical agents are among the most common recommended treatments for the management of xerostomia. These include chewing gums, saliva stimulants, and substitutes. A topical sialogogue spray containing 1% malic acid has recently shown its efficacy in managing symptoms of xerostomia in patients with antidepressant- or antihypertensive-induced dry mouth;Citation49,Citation50 however, this has the potential to cause mild enamel erosion. Commercially available sugar-free chewing gums and candies can also be used to simulate salivary flow.Citation51 In particular, chewing gums have been shown to increase saliva secretion and decrease oral mucosal friction.Citation52 In addition to chewing gum, saliva stimulants and substitutes (eg, gel, mouthwash, and toothpaste) provide over-the-counter alternatives for salivary gland hypofunction management. Other oral sprays, specifically oxygenated glycerol tri-ester, serve as an alternative treatment for dry mouth and have been proven to be more effective than other commercially available saliva substitutes.Citation53 Saliva substitutes aim to increase viscosity and mimic natural saliva without altering the salivary flow.Citation54 These agents contain minerals (eg, fluoride, calcium, and phosphate ions), carboxymethylcellulose or hydroxyethylcellulose, flavoring agents, and preservatives (eg, propyl or methyl paraben).Citation38 Other efficacious remedies include mucoadhesive lipid-based bioerodible tabletsCitation55 or mucin spray, although their efficacy for management of xerostomia remains controversial.Citation51,Citation56Citation59 Mucin-containing lozenges provided benefit for the treatment of xerostomia when compared to a placebo.Citation60 Other topical agents (toothpaste, mouth rinse, mouth spray, and gel) containing olive oil, betaine, and xylitol may be effective in improving xerostomia secondary to medication use.Citation61 Of note, saliva substitute spray containing carboxymethylcellulose,Citation62 xanthan gum-containing spray,Citation63 or buffered Profylin gelCitation64 did not seem to improve dry mouth symptoms. Also lemon lozenge use in individuals with xerostomia did not show any increase in salivary flow when compared to baseline paraffin-stimulated mean flow rate and the gum-stimulated flow rates.Citation65 Of interest, Regelink et al reported that saliva substitutes are not effective in patients with reasonable stimulated salivary flow.Citation66

The saliva substitute Saliva Orthana, a mucin-containing oral spray, was tested in a double-blind, single-phase, placebo-controlled trial for patients complaining of xerostomia.Citation59 The results of this study did not show any significant improvement when compared to the placebo. When oral lubricants are considered, the gel formulation appears to be the most efficient and appreciated by patients.Citation67 Patients taking oral lozenges of anhydrous crystalline maltose showed an increase in saliva production and a decrease in perceived symptoms of xerostomia.Citation68 Patients applying the anticholinesterase physostigmine on the oral mucosa to stimulate salivary production from the minor glands reported great benefit, and this could be a valid alternative to systemic treatment.Citation69

Changes in medications

Although the evidence available is limited, with patients on medications known to induce salivary gland hypofunction, a treatment alternative includes decreasing the dosage of the medications or potentially replacing the medications with less xerogenic drugs.Citation70 Studies have shown that xerostomia became more manageable through medication dose reduction and medication replacement.Citation71,Citation72 Any change in medication should be discussed with the referring physician.

Others

Other remedies have been proposed for the management of xerostomia. Intraoral electrostimulation has also been tested to increase salivary flow.Citation73,Citation74 Furthermore, reports have shown that intraoral appliances, such as the saliva stimulation device Saliwell Crown or the electrostimulating device GenNarino, have been effective in reducing dry mouth and increasing the production of saliva.Citation75 Acupuncture may be a useful adjunct for the stimulation of salivary flow in some patients with xerostomia and in patients with irradiation-induced xerostomia. However, additional larger studies are necessary to confirm these findings.Citation76,Citation77

Finally, patients who undergo radiation of the head and neck region may benefit from the use of intensity-modified radiation therapy and/or of amifostine (cytoprotective agent).Citation78

Conclusion

Xerostomia and hyposalivation remain a debilitating condition for many individuals. This review summarizes the diagnostic and therapeutic approaches to manage xerostomia and hyposalivation. Clinicians with a patient complaining of xerostomia have the opportunity to identify patients with true salivary gland hypofunction with effective diagnostic criteria and functional tests, and therefore prevent secondary effects. Although no standard treatment guidelines are available, many treatment options exist for the management of xerostomia and hyposalivation: topical agents to alleviate and/or prevent xerostomia, systemic therapy, or newer devices. While systemic agents such as pilocarpine or cevimeline have been largely studied, new medical devices require large well-designed clinical trials.

Disclosure

The authors report no conflicts of interest in this work.

References

  • HopcraftMSTanCXerostomia: an update for cliniciansAust Dent J2010553238244 quiz 35320887509
  • van der PuttenGJBrandHSScholsJMde BaatCThe diagnostic suitability of a xerostomia questionnaire and the association between xerostomia, hyposalivation and medication use in a group of nursing home residentsClin Oral Investig2011152185192
  • FoxPCvan der VenPFSoniesBCWeiffenbachJMBaumBJXerostomia: evaluation of a symptom with increasing significanceJ Am Dent Assoc198511045195253858368
  • HumphreySPWilliamsonRTA review of saliva: normal composition, flow, and functionJ Prosthet Dent200185216216911208206
  • PedersenAMBardowAJensenSBNauntofteBSaliva and gastrointestinal functions of taste, mastication, swallowing and digestionOral Dis20028311712912108756
  • HeintzeUBirkhedDBjörnHSecretion rate and buffer effect of resting and stimulated whole saliva as a function of age and sexSwed Dent J1983762272386583873
  • SreebnyLMVissinkADry Mouth: the malevolent symptom A clinical guideAmesWiley-Blackwell2010
  • DawesCHow much saliva is enough for avoidance of xerostomia?Caries Res200438323624015153694
  • CassolatoSFTurnbullRSXerostomia: clinical aspects and treatmentGerodontology2003202647714697016
  • VillaAPolimeniAStrohmengerLCicciùDGherloneEAbatiSDental patients’ self-reports of xerostomia and associated risk factorsJ Am Dent Assoc2011142781181621719803
  • EkströmJKhosravaniNCastagnolaMMessanaISaliva and the control of its secretionEkbergODysphagia: Diagnosis and TreatmentBerlinSpringer-Verlag20121947
  • ThomsonWMIssues in the epidemiological investigation of dry mouthGerodontology2005222657615934347
  • BergdahlMBergdahlJLow unstimulated salivary flow and subjective oral dryness: association with medication, anxiety, depression, and stressJ Dent Res20007991652165811023259
  • LealSCBittarJPortugalAFalcãoDPFaberJZanottaPMedication in elderly people: its influence on salivary pattern, signs and symptoms of dry mouthGerodontology201027212913320337727
  • AstorFCHanftKLCioconJOXerostomia: a prevalent condition in the elderlyEar Nose Throat J199978747647910429321
  • LiuBDionMRJurasicMMGibsonGJonesJAXerostomia and salivary hypofunction in vulnerable elders: prevalence and etiologyOral Surg Oral Med Oral Pathol Oral Radiol20121141526022727092
  • LockerDSubjective reports of oral dryness in an older adult populationCommunity Dent Oral Epidemiol19932131651688348792
  • ThorseliusIEmilsonCGOsterbergTSalivary conditions and drug consumption in older age groups of elderly Swedish individualsGerodontics19884266703209028
  • NaglerRMSalivary glands and the aging process: mechanistic aspects, health-status and medicinal-efficacy monitoringBiogerontology20045422323315314272
  • ValdezIHFoxPCDiagnosis and management of salivary dysfunctionCrit Rev Oral Biol Med199343–42712778373984
  • FoxPCBuschKABaumBJSubjective reports of xerostomia and objective measures of salivary gland performanceJ Am Dent Assoc198711545815843477595
  • ThomsonWMChalmersJMSpencerAJWilliamsSMThe Xerostomia Inventory: a multi-item approach to measuring dry mouthCommunity Dent Health1999161121710697349
  • SreebnyLMValdiniAXerostomia. Part I: Relationship to other oral symptoms and salivary gland hypofunctionOral Surg Oral Med Oral Pathol19886644514583186220
  • EisbruchARhodusNRosenthalDHow should we measure and report radiotherapy-induced xerostomia?Semin Radiat Oncol200313322623412903012
  • PaiSGhezziEMShipJADevelopment of a Visual Analogue Scale questionnaire for subjective assessment of salivary dysfunctionOral Surg Oral Med Oral Pathol Oral Radiol Endod200191331131611250628
  • SinghMLPapasAOral Implications of Polypharmacy in the ElderlyDent Clin North Am201458478379625201542
  • SmidtDTorpetLANauntofteBHeegaardKMPedersenAMAssociations between labial and whole salivary flow rates, systemic diseases and medications in a sample of older peopleCommunity Dent Oral Epidemiol201038542243520545715
  • OsailanSPramanikRShirodariaSChallacombeSJProctorGBInvestigating the relationship between hyposalivation and mucosal wetnessOral Dis201117110911421029258
  • LöfgrenCDWickströmCSonessonMLagunasPTChristerssonCA systematic review of methods to diagnose oral dryness and salivary gland functionBMC Oral Health2012122922870895
  • NavazeshMMethods for collecting salivaAnn N Y Acad Sci199369472778215087
  • ChenAWaiYLeeLLakeSWooSBUsing the modified Schirmer test to measure mouth dryness: a preliminary studyJ Am Dent Assoc20051362164170 quiz 229–23015782519
  • NavazeshMKumarSKUniversity of Southern California School of DentistryMeasuring salivary flow: challenges and opportunitiesJ Am Dent Assoc2008139Suppl35S40S18460678
  • LashleyKSReflex secretion of the human parotid glandJ Exp Psychol191616461493
  • SchneyerLHMethod for the collection of separate submaxillary and sublingual salivas in manJ Dent Res195534225726114367622
  • WolffABegleiterAMoskonaDA novel system of human submandibular/sublingual saliva collectionJ Dent Res19977611178217869372796
  • EliassonLCarlénAAn update on minor salivary gland secretionsEur J Oral Sci2010118543544220831576
  • SmidtDTorpetLANauntofteBHeegaardKMPedersenAMAssociations between oral and ocular dryness, labial and whole salivary flow rates, systemic diseases and medications in a sample of older peopleCommunity Dent Oral Epidemiol201139327628821070322
  • VisvanathanVNixPManaging the patient presenting with xerostomia: a reviewInt J Clin Pract201064340440719817913
  • TakakuraACMoreiraTSLaitanoSCDe Luca JúniorLARenziAMenaniJVCentral muscarinic receptors signal pilocarpine-induced salivationJ Dent Res2003821299399714630901
  • WisemanLRFauldsDOral pilocarpine: a review of its pharmacological properties and clinical potential in xerostomiaDrugs19954911431557705213
  • IwabuchiYMasuharaTSialogogic activities of SNI-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: identification of a potential therapeutic agent for treatment of Sjorgen’s syndromeGen Pharmacol19942511231297517901
  • IwabuchiYKatagiriMMasuharaTSalivary secretion and histopathological effects after single administration of the muscarinic agonist SNI-2011 in MRL/lpr miceArch Int Pharmacodyn Ther199432833153257542865
  • WeberJKeatingGMCevimelineDrugs200868121691169818681491
  • ChambersMSJonesCUBielMAOpen-label, long-term safety study of cevimeline in the treatment of postirradiation xerostomiaInt J Radiat Oncol Biol Phys20076951369137617855005
  • BragaMATarziaOBergamaschiCCSantosFAAndradeEDGroppoFCComparison of the effects of pilocarpine and cevimeline on salivary flowInt J Dent Hyg20097212613019416095
  • AframianDJHelcerMLivniDRobinsonSDMarkitziuANadlerCPilocarpine treatment in a mixed cohort of xerostomic patientsOral Dis2007131889217241436
  • HamadaTNakaneTKimuraTTreatment of xerostomia with the bile secretion-stimulating drug anethole trithione: a clinical trialAm J Med Sci1999318314615110487404
  • BagheriHSchmittLBerlanMMontastrucJLA comparative study of the effects of yohimbine and anetholtrithione on salivary secretion in depressed patients treated with psychotropic drugsEur J Clin Pharmacol19975253393429272401
  • Gómez-MorenoGGuardiaJAguilar-SalvatierraACabrera-AyalaMMaté-Sánchez de-ValJECalvo-GuiradoJLEffectiveness of malic acid 1% in patients with xerostomia induced by antihypertensive drugsMed Oral Patol Oral Cir Bucal2013181e49e5522926481
  • Gómez-MorenoGAguilar-SalvatierraAGuardiaJThe efficacy of a topical sialogogue spray containing 1% malic acid in patients with antidepressant-induced dry mouth: a double-blind, randomized clinical trialDepress Anxiety201330213714223124914
  • FurnessSWorthingtonHVBryanGBirchenoughSMcMillanRInterventions for the management of dry mouth: topical therapiesCochrane Database Syst Rev201112CD00893422161442
  • OlssonHSpakCJAxéllTThe effect of a chewing gum on salivary secretion, oral mucosal friction, and the feeling of dry mouth in xerostomic patientsActa Odontol Scand19914952732791803848
  • MoulySJOrlerJBTilletYEfficacy of a new oral lubricant solution in the management of psychotropic drug-induced xerostomia: a randomized controlled trialJ Clin Psychopharmacol200727543744317873673
  • van der ReijdenWAVissinkAVeermanECAmerongenAVTreatment of oral dryness related complaints (xerostomia) in Sjögren’s syndromeAnn Rheum Dis199958846547410419864
  • AframianDJMizrahiBGranotIDombAJEvaluation of a mucoadhesive lipid-based bioerodable tablet compared with Biotène mouthwash for dry mouth relief – a pilot studyQuintessence Int2010413e36e4220213013
  • Blixt-JohansenGEkACGanowiakWImprovement of oral mucosa with mucin containing artificial saliva in geriatric patientsArch Gerontol Geriatr199214219320115374404
  • DuxburyAJThakkerNSWastellDGA double-blind cross-over trial of a mucin-containing artificial salivaBr Dent J198916641151202465774
  • van der ReijdenWAvan der KwaakHVissinkAVeermanECAmerongenAVTreatment of xerostomia with polymer-based saliva substitutes in patients with Sjögren’s syndromeArthritis Rheum199639157638546739
  • SweeneyMPBaggJBaxterWPAitchisonTCClinical trial of a mucin-containing oral spray for treatment of xerostomia in hospice patientsPalliat Med19971132252329205656
  • GravenmadeEJVissinkAMucin-containing lozenges in the treatment of intraoral problems associated with Sjögren’s syndrome. A double-blind crossover study in 42 patientsOral Surg Oral Med Oral Pathol19937544664718464611
  • ShipJAMcCutcheonJASpivakovskySKerrARSafety and effectiveness of topical dry mouth products containing olive oil, betaine, and xylitol in reducing xerostomia for polypharmacy-induced dry mouthJ Oral Rehabil2007341072473217824884
  • DonatskyOJohnsenTHolmstrupPBertramUEffect of Saliment on parotid salivary gland secretion and on xerostomia caused by Sjögren’s syndromeScand J Dent Res19829021571627041242
  • JellemaAPLangendijkHBergenhenegouwenLThe efficacy of Xialine in patients with xerostomia resulting from radiotherapy for head and neck cancer: a pilot-studyRadiother Oncol200159215716011325444
  • PerssonALingströmPBergdahlMClaessonRvan DijkenJWBuffering effect of a prophylactic gel on dental plaque in institutionalised elderlyGerodontology20072429810417518957
  • StewartCMJonesACBatesRESandowPPinkFStillwellJComparison between saliva stimulants and a saliva substitute in patients with xerostomia and hyposalivationSpec Care Dentist199818414214810218061
  • RegelinkGVissinkAReintsemaHNautaJMEfficacy of a synthetic polymer saliva substitute in reducing oral complaints of patients suffering from irradiation-induced xerostomiaQuintessence Int19982963833889728149
  • FurumotoEKBarkerGJCarter-HansonCBarkerBFSubjective and clinical evaluation of oral lubricants in xerostomic patientsSpec Care Dentist19981831131189680921
  • FoxPCCumminsMJCumminsJMUse of orally administered anhydrous crystalline maltose for relief of dry mouthJ Altern Complement Med200171334311246934
  • KhosravaniNBirkhedDEkströmJThe cholinesterase inhibitor physostigmine for the local treatment of dry mouth: a randomized studyEur J Oral Sci200911720921719583746
  • SreebnyLMValdiniAXerostomia. A neglected symptomArch Intern Med19871477133313373300589
  • AzodoCCEzejaEBOmoaregbaJOJamesBOOral health of psychiatric patients: the nurse’s perspectiveInt J Dent Hyg201210424524922192470
  • TrindadeEMenonDTopferLAColomaCAdverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysisCMAJ199815910124512529861221
  • StrietzelFPLafaurieGIMendozaGREfficacy and safety of an intraoral electrostimulation device for xerostomia relief: a multicenter, randomized trialArthritis Rheum201163118019020882668
  • StrietzelFPMartin-GranizoRFedeleSElectrostimulating device in the management of xerostomiaOral Dis200713220621317305624
  • AlajbegIFalcãoDPTranSDIntraoral electrostimulator for xerostomia relief: a long-term, multicenter, open-label, uncontrolled, clinical trialOral Surg Oral Med Oral Pathol Oral Radiol2012113677378122668705
  • BlomMDawidsonIAngmar-MånssonBThe effect of acupuncture on salivary flow rates in patients with xerostomiaOral Surg Oral Med Oral Pathol19927332932981545961
  • O’SullivanEMHigginsonIJClinical effectiveness and safety of acupuncture in the treatment of irradiation-induced xerostomia in patients with head and neck cancer: a systematic reviewAcupunct Med201028419119921062848
  • GuJZhuSLiXWuHLiYHuaFEffect of amifostine in head and neck cancer patients treated with radiotherapy: a systematic review and meta-analysis based on randomized controlled trialsPLoS One201495e9596824788761